Enzalutamide (NCT06096870)

Name: Enzalutamide trial for Prostate Cancer (NCT06096870)
Uploaded: 2026-10-31T06:27:38.223Z
Duration: 1 min 36 s
Description: Enzalutamide trial for Prostate Cancer (NCT06096870). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06096870.

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy: a one-minute explainerNCT060968701 min

Enzalutamide trial for Prostate Cancer (NCT06096870). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for men aged 18–120 with prostate cancer recurring after surgery or radiation, visible on PSMA PET. PSA must double within twelve months, testosterone exceed 100 ng/dL, and scans meet criteria.

The idea: compare enzalutamide alone with enzalutamide plus PDS01ADC, without testosterone-lowering therapy. Enzalutamide blocks androgen receptors; PDS01ADC targets dead tumor tissue to deliver immune stimulation. Treatment lasts three four-week cycles. One enzalutamide retreatment may follow PSA recovery. Researchers measure PSA suppression duration.

This phase 2 study plans 65 patients. Melissa Abel leads at NIH in Bethesda, one recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.